Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23350956 | 0.85 | MAP3K14 (0.31) | — | |
| SCHEMBL12401856 | 0.79 | SMN1; SMN2 (0.42) | ALDH1A1CYP3A4POLBSMN1; SMN2 | |
| SCHEMBL9979060 | 0.79 | GABBR2 (0.36) | ALDH1A1CYP3A4POLBSMN1; SMN2 | |
| SCHEMBL15180075 | 0.75 | CA1 (0.47) | ALDH1A1CYP3A4POLBSMN1; SMN2MEN1 | |
| SCHEMBL12484333 | 0.75 | NPC1 (0.37) | ALDH1A1CYP3A4POLBSMN1; SMN2DYRK1A | |
| SCHEMBL12404705 | 0.74 | GABRA1 (0.44) | ALDH1A1CYP3A4SMN1; SMN2DYRK1AGSK3B | |
| SCHEMBL11081166 | 0.74 | AHR (0.47) | ALDH1A1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12401760 | 0.74 | TSHR (0.40) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23802154 | 0.74 | ALDH1A1 (0.47) | ALDH1A1CYP3A4POLBSMN1; SMN2 | |
| SCHEMBL12467259 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CYP3A4POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | ALDH1A1 1255/4885CYP3A4 158/4885POLB 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.